Best Practices for Pregnant Incarcerated Women With Opioid Use Disorder

Overview

Journal J Correct Health Care

Publisher Mary Ann Liebert

Specialties Health Services
Public Health

Date 2019 Jan 9

PMID 30616487

Citations 6

Authors

Mary Peeler

Kevin Fiscella

Mishka Terplan

Carolyn Sufrin

Affiliations

Soon will be listed here.

Abstract

Pregnant women represent a unique population for correctional facilities to care for. The incarcerated pregnant population is at an increased risk of concurrent opioid use disorder (OUD) that requires specialized care. The evidence-based best practice and standard of care for pregnant women with OUD is medication-assisted treatment (MAT) with methadone or buprenorphine pharmacotherapy. Correctional facilities that house women must be prepared to provide this care in a timely manner upon intake in order to address the serious medical needs of the pregnant woman and her fetus. Providing MAT in the incarceration setting has distinctive logistics that must be considered. This article recommends strategies to optimize the care of pregnant incarcerated women with OUD, emphasizing the importance of appropriate counseling and treatment with opioid agonist pharmacotherapy.

Citing Articles

Access to Services for Pregnant People With Opioid Use Disorder in Jails in the United States.

Grella C, Scott C, Dennis M, LaVallee R J Correct Health Care. 2023; 29(4):299-307.

PMID: 37252747 PMC: 10494905. DOI: 10.1089/jchc.22.03.0023.

Development and use of a checklist for the implementation of medication for opioid use disorder in jails.

Ludwig A, Monico L, Blue T, Gordon M, Schwartz R, Mitchell S Implement Res Pract. 2023; 3:26334895221101214.

PMID: 37091098 PMC: 9924266. DOI: 10.1177/26334895221101214.

An integrative literature review of substance use treatment service need and provision to pregnant and postpartum populations in carceral settings.

Steely Smith M, Wilson S, Zielinski M Womens Health (Lond). 2023; 19:17455057221147802.

PMID: 36920150 PMC: 10021089. DOI: 10.1177/17455057221147802.

Shackling and pregnancy care policies in US prisons and jails.

Kramer C, Thomas K, Patil A, Hayes C, Sufrin C Matern Child Health J. 2022; 27(1):186-196.

PMID: 36372806 PMC: 9660187. DOI: 10.1007/s10995-022-03526-y.

Care for Incarcerated Pregnant People With Opioid Use Disorder: Equity and Justice Implications.

Ahlbach C, Sufrin C, Shlafer R Obstet Gynecol. 2020; 136(3):576-581.

PMID: 32769655 PMC: 7483637. DOI: 10.1097/AOG.0000000000004002.

References

Waal H . Is sustained release natrexone an option for heroin-dependent pregnant women?. Addiction. 2013; 108(2):252-3. DOI: 10.1111/j.1360-0443.2012.03940.x. View

Chandler R, Fletcher B, Volkow N . Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA. 2009; 301(2):183-90. PMC: 2681083. DOI: 10.1001/jama.2008.976. View

Jones H, OGrady K, Malfi D, Tuten M . Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008; 17(5):372-86. DOI: 10.1080/10550490802266276. View

Rich J, McKenzie M, Larney S, Wong J, Tran L, Clarke J . Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015; 386(9991):350-9. PMC: 4522212. DOI: 10.1016/S0140-6736(14)62338-2. View

Lee J, Friedmann P, Kinlock T, Nunes E, Boney T, Hoskinson Jr R . Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016; 374(13):1232-42. PMC: 5454800. DOI: 10.1056/NEJMoa1505409. View

Mitchell S, Kelly S, Brown B, Reisinger H, Peterson J, Ruhf A . Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users. J Psychoactive Drugs. 2009; 41(2):145-52. PMC: 2838492. DOI: 10.1080/02791072.2009.10399907. View

Kampman K, Jarvis M . American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med. 2015; 9(5):358-67. PMC: 4605275. DOI: 10.1097/ADM.0000000000000166. View

Zedler B, Mann A, Kim M, Amick H, Joyce A, Murrelle E . Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction. 2016; 111(12):2115-2128. PMC: 5129590. DOI: 10.1111/add.13462. View

Tolia V, Patrick S, Bennett M, Murthy K, Sousa J, Smith P . Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med. 2015; 372(22):2118-26. DOI: 10.1056/NEJMsa1500439. View

10.

Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich J . Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009; 105(1-2):83-8. PMC: 2743749. DOI: 10.1016/j.drugalcdep.2009.06.015. View

11.

Volkow N, Koob G, McLellan A . Neurobiologic Advances from the Brain Disease Model of Addiction. N Engl J Med. 2016; 374(4):363-71. PMC: 6135257. DOI: 10.1056/NEJMra1511480. View

12.

Binswanger I, Blatchford P, Mueller S, Stern M . Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013; 159(9):592-600. PMC: 5242316. DOI: 10.7326/0003-4819-159-9-201311050-00005. View

13.

Rich J, Wakeman S, Dickman S . Medicine and the epidemic of incarceration in the United States. N Engl J Med. 2011; 364(22):2081-3. PMC: 3154686. DOI: 10.1056/NEJMp1102385. View

14.

Haight S, Ko J, Tong V, Bohm M, Callaghan W . Opioid Use Disorder Documented at Delivery Hospitalization - United States, 1999-2014. MMWR Morb Mortal Wkly Rep. 2018; 67(31):845-849. PMC: 6089335. DOI: 10.15585/mmwr.mm6731a1. View

15.

Staton M, Leukefeld C, Webster J . Substance use, health, and mental health: problems and service utilization among incarcerated women. Int J Offender Ther Comp Criminol. 2003; 47(2):224-39. DOI: 10.1177/0306624X03251120. View

16.

Krans E, Cochran G, Bogen D . Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations. Clin Obstet Gynecol. 2015; 58(2):370-9. PMC: 4607033. DOI: 10.1097/GRF.0000000000000098. View

17.

Fiscella K . Guidelines and Quality Measures Should Reflect Evidence for Effectiveness of Naltrexone. J Addict Med. 2016; 10(6):453. DOI: 10.1097/ADM.0000000000000265. View

18.

Mattick R, Breen C, Kimber J, Davoli M . Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003; (4):CD002209. DOI: 10.1002/14651858.CD002209. View

19.

. Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017; 130(2):e81-e94. DOI: 10.1097/AOG.0000000000002235. View

20.

Rudd R, Seth P, David F, Scholl L . Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016; 65(50-51):1445-1452. DOI: 10.15585/mmwr.mm655051e1. View